anti-LeY-scFv-CD28-zeta CAR T-cells

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameanti-LeY-scFv-CD28-zeta CAR T-cells
Drug Alias Nameanti-Lewis Y CAR T-cell therapy (Peter MacCallum Cancer Centre/Juno Therapeutics)anti-Lewis Y CAR T-cell therapy (Peter MacCallum Cancer Centre/Bristol-Myers Squibb)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionT lymphocytes stimulantsImmunostimulants
TargetsUpdating
Therapy Area/IndicationsSolid tumoursProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia and New Zealand
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesPeter Maccallum Cancer Centre
China Registration ClassN/A

Develop Information

Active CompaniesPeter Maccallum Cancer CentreBristol-Myers Squibb Company
Inactive CompaniesCelgene CorpJuno Therapeutics Inc
Active IndicationsSolid tumoursProstatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A